Background/Aims: There are few effective treatment options for hypertrophic scars. MircoRNAs are a class of small, noncoding RNAs involved in multiple biological functions. Methods: Gene chip screening was used to screen out the differential expression of miRNAs in hypertrophic scars and normal tissues. Western blot and real-time PCR were used to confirm the expression of pleiotrophin (PTN) in hypertrophic scars. After analyze the correlation between PTN and miR-137 using correlation analysis, we used miRDB software to analyze the binding sites of miR-137 and PTN. Luciferase reporter gene, western blot and real-time PCR experiments were used to detect the regulatory effect of miR-137 on PTN. MTT and transwell assay were used to detect the effect of miR-137 on proliferation and metastasis. Western blot and real-time PCR were used to detect the regulatory effects of miR-137 on cyclin B1, matrix metalloproteinase 9 (MMP9), α-smooth muscle actin (α-SMA), vimentin, and type-I collagen (COL1A). Finally, miR-137 inhibitor was transfected into fibroblasts which was silent PTN, and the proliferation and migration of cells were detected by MTT and transwell. Western blot and real-time PCR were used to detect the expression of related proteins. Results: Various miRNAs was abnormal expressed in hypertrophic scars. miR-137 was decreased in hypertrophic scar, however PTN was up regulated in hypertrophic scars. miR-137 induced proliferation and metastasis in fibroblasts. This effect was accompanied by decreased expression of cyclin B1, MMP9, α-SMA, vimentin, and COL1A mediated via the target of PTN. Conclusion: Modulation of miR-137 expression in fibroblasts could provide an important therapeutic strategy for hypertrophic scars.
Introduction
Hypertrophic scar and keloid are two types of pathological scar [1] . Patients with hypertrophic scars experience physical pain and stress, such as itching and skin contraction, as well as psychological distress. In addition to surgery, current treatments for hypertrophic scars mainly include glucocorticoid injection, silicone membrane therapy, compression therapy, cryotherapy, laser therapy, radiotherapy, and interferon growth factor therapy [2] . Each type of therapy usually requires multiple treatments and has some limitations. Thus, more convenient, effective, and safe methods for the treatment of hypertrophic scars are needed [3, 4] .
Increasing evidence implicates mircoRNAs (miRNAs) as important regulatory factors in tumorigenesis and hypertrophic scars, and they are found to be dysregulated in the majority of analyzed cancers and pathological scars [5] [6] [7] .
Pleiotrophin (PTN) is a secreted, heparin-binding growth factor that has a role in various biological functions such as cell growth, differentiation, and tumor progression. PTN expression was reported to be increased in hypertrophic scars [8] .
In this study, we demonstrated that miR-137 induced proliferation, metastasis and differentiation in fibroblasts. This effect was accompanied by decreased expression of cyclin B1, matrix metalloproteinase 9 (MMP9), α-smooth muscle actin (α-SMA), vimentin, and type-I collagen (COL1A) mediated via the PTN pathway. These results suggest that modulation of miR-137 expression in fibroblasts could provide an important therapeutic strategy for hypertrophic scars and warrants further investigation. Healthy skin and hypertrophic scar tissues were minced, and epidermal and dermal layers were separated by treatment with dispase II (Life Technologies, Carlsbad, CA) for the isolation of primary human skin fibroblasts and hypertrophic scar fibroblasts. Tissue was digested with collagenase type I (SigmaAldrich, St. Louis, MO). Fibroblasts were harvested and grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone Technologies, Logan, UT), at 37 °C in 5% CO 2 . Fibroblasts at passages 2-5 were used for all experiments in this study [9] .
Materials and Methods

Tissue samples and cell lines
RNA isolation
Total RNAs were extracted from tissues and cells using miRcute miRNA Isolation Kit (Tiangen Biotech (Beijing) Co., Ltd., Beijing, China) according to the manufacturer's instruction. Samples were stored at -80°C.
miRNA microarray analysis A total of 500 ng RNA was subjected to Agilent miRNA microarray analysis (RiboBio, Beijing, China). Differences between groups were examined for statistical significance using unpaired Student's t-test.
Real-time PCR
Real-time PCR was performed using Real-time PCR Universal Reagent and the MX3000P Real-time PCR instrument following the manufacturer's protocols (Suobao, Shanghai, China). U6 small nuclear RNA was used as an internal control. The expression of miR-137 was detected using the Stem-Loop RT-PCR assay as previously reported [10, 11] . Primer sequences are listed in Table 1 .
All reactions were carried out as described previously [12] . Western blot analyses Cells and tissues were lysed and protein was extracted using lysate buffer. Lysate was prepared using NP40 buffer supplemented with proteinase inhibitor cocktail. Samples were resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membranes. PVDF membranes were blocked with phosphate-buffered saline containing 2% bovine serum albumin and 0.05% Tween-20 overnight at 4°C. Membranes were then probed with primary antibodies for 1 h at room temperature. Next, membranes were washed and incubated with goat-anti-mouse secondary antibody for 1 h at room temperature. Expression levels of relevant proteins were quantified and normalized relative to GAPDH. Antibodies used for western blotting were: anti-PTN (1:300), anti-cyclin B1 (1:500), anti-MMP9 (1:500), anti-α-smooth muscle actin (α-SMA) (1:300), anti-vimentin (1:500), anti-type-I collagen (COL1A; 1:500), and anti-GAPDH (1:1000), and horseradish peroxidase-conjugated anti-mouse (1:5000) and anti-rabbit (1:5000) secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
Dual luciferase reporter assay
Dual luciferase activity assays were performed as previously described [13] . The PTN 3' untranslated region (3'-UTR) was PCR amplified and cloned into the pMiR-REPORT TM vector (Ambion, Shanghai, China). The primers were: PTN-WT, F: 5'-CAATTCCCCGTCCCTCCAAA -3', R: 5'-TGTGCATGACATCCAACTGAA -3', PTN-mut (the site of miR-137 binding was mutated), F: 5'-CCCCGTCCCTCCAAAATCTC -3', R: 5'-TTGTGCATGACATCCAACTGA -3'. Cells were seeded and co-transfected with the above constructs and miR-137 mimic (RiboBio), miR-137 antisense (RiboBio) or control (RiboBio). After 24 h, fibroblasts were harvested and luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System (Biotek Synergy, Beijing, China).
MTT assay
Cell proliferation was measured using the MTT assay (Solarbio, Beijing, China). Cells were seeded at a density of 1 × 10 3 cells per well in 96-well plates, and transfected with miR-137 mimic, miR-137 inhibitor (RiboBio), or negative control; then, cell proliferation was evaluated by MTT assay. A microplate reader (Bio-Rad Laboratories, Hercules, CA) was used to measure optical density at 490 nm.
Transwell migration assay
Twenty-four hours after transfection with miR-137 mimic, miR-137 inhibitor, or negative control, 1 × 10 5 cells in serum-free medium were seeded in transwell chambers with or without a Matrigel cover. and the transwell migration assay was performed. After 8 h, cells were fixed with 4% paraformaldehyde and stained with 0.4% trypan blue.
Measurement of contraction rate of fibroblast collagen network
Control, miR-137 mimic, or miR-137 inhibitor was transfected into human skin fibroblasts and hypertrophic scar fibroblasts. After transfection for 24 h, 2 × 10 4 cells were mixed with 100 μL collagen solution (Boosen, Beijing, China) with 300 μL 10 × DMEM. After mixing, the cells were incubated at 37°C for 10 min, then 2 mL DMEM was added. After the gel was separated from the bottom wall of the culture dish, the culture was maintained at 37°C. The gel diameter was measured at 0, 24, and 48 h, and the shrinkage index of the gel block was calculated.
Statistical analysis
All data were analyzed with SPSS 17.0 (SPSS Inc., Chicago, IL). Statistical significance was defined as P < 0.05. All experiments were repeated three times.
Results
Differential expression profile of miRNAs in hypertrophic scar tissues
The miRNA microarray showed 10 underexpressed miRNAs (P < 0.05) and 8 overexpressed miRNAs (P < 0.05) in hypertrophic scar tissues compared with the adjacent normal tissues (Table 2) . Among these 18 mRNAs, we found a fold change of >30 in 9 miRNAs, with the largest fold change (71.253) for miR-137. The expressions of these miRNAs in hypertrophic scar tissues and adjacent normal tissues were detected by real-time PCR (Fig.  1A) . The results showed that miR-137 decreased significantly in hypertrophic scar tissues.
The expression of PTN in hypertrophic scar tissues
Using MiRDB software, we showed that miR-137 can target multiple proteins. Among them PTN, a previously identified protein overexpressed in hypertrophic scars, has been shown to bind to miR-137. The expression of PTN in hypertrophic scar tissues and adjacent tissues was detected by western blotting and real-time PCR (Fig. 1 B, C) . Results showed that there was a higher expression of PTN in hypertrophic scar tissues than the adjacent tissues.
Relationship between miR-137 and PTN in hypertrophic scar fibroblasts
Using correlation analysis, we found a negative association between the expressions of miR-137 and PTN in hypertrophic scars (Fig. 2A) . We also found that miR-137 could be combined (Fig. 2B) . A luciferase reporter assay showed that miR-137 can reduce the expression of PTN at the transcriptional level in hypertrophic scar fibroblasts (Fig.  2C ). When cells were co-transfected with PTN and miR-137, luciferase activity was reduced; however, luciferase activity did not vary significantly in the cells co-transfected with PTN mut or miR-137 antisense. Next, we transfected miR-137 mimic or miR-137 inhibitor into human skin fibroblasts and hypertrophic scar fibroblasts, and western blotting and real-time PCR showed that the expression levels of PTN, α-SMA, vimentin, and COL1A were downregulated significantly by miR-137 (Fig. 2D-G) . We also found that the collagen gel started to shrink within 1 day of seeding the hypertrophic scar fibroblasts, and the area gradually reached 40% of its initial size over the next 5 days. Transfection of miR-137 mimic/inhibitor in fibroblasts had minimal effect on the size of the gel over the 5 days (Fig. 2H) . 
miR-137 inhibits the proliferation of hypertrophic scar fibroblasts by suppressing cyclin B1
The proliferation of hypertrophic scar fibroblasts was measured using the MTT assay after transfection of miR-637 mimic or inhibitor into fibroblasts. We found that miR-137 mimic could inhibit proliferation of hypertrophic scar fibroblasts and miR-137 inhibitor could promote the proliferation of hypertrophic scar fibroblasts (Fig. 3A, B) . Studies have shown that PTN can affect the cell cycle-related protein cyclin B1 by regulating the signaling pathway. Thus, the expression of cyclin B1 in hypertrophic scar fibroblasts with overexpression or underexpression of miR-137 was detected by western blotting and realtime PCR. The results showed that miR-137 could significantly inhibit the expression of cyclin B1 (Fig. 3C-F) . 
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miR-137 inhibits the metastasis of hypertrophic scar fibroblasts by suppressing MMP9
High expression of PTN has been shown to affect cell metastasis by regulating MMPs [14] . The transwell assay (with or without Matrigel) was used to study the role of miR-137 in metastasis of hypertrophic scar fibroblasts (Fig. 4A-D) . We found that both migration and invasion of hypertrophic scar fibroblasts could be significantly inhibited by miR-137. In addition, western blotting and real-time PCR showed that MMP9 was significantly downregulated by miR-137 (Fig. 4E-H) .
Effects of miR-137 small interfering RNA and PTN siRNA on cell proliferation and metastasis in hypertrophic scar fibroblasts
We explored the effects of miR-137 small interfering RNA (siRNA) and PTN siRNA on cell proliferation and metastasis in hypertrophic scar fibroblasts. MTT and transwell assays showed that PTN siRNA significantly suppressed cell proliferation and metastasis (Fig. 5A,  B) . When both miR-137 and PTN were inhibited, proliferation and migration of the cells were reduced compared with the use of miR-137 alone, but proliferation and migration were increased compared with the use of si-PTN alone. In order to explore the underlying molecular mechanisms, cyclin B1 and MMP9 expression levels were determined. Co- (Fig. 5C, D) . These results suggest that miR-137 may regulate the proliferation and metastasis of hypertrophic scar fibroblasts by targeting PTN.
Discussion
Results demonstrated that miR-21 can promote the occurrence and development of hypertrophic scars through regulation of human telomerase reverse transcriptase via phosphatase and tensin homolog [15] . miR-98 inhibits cell proliferation via targeting Col1A1 in human hypertrophic scar fibroblasts [16] , and miR-181b may be a potential therapy for hypertrophic scar [17] . Furthermore, miR-137 was decreased in several cancers, and a low miR-137 level was an independent risk factor for cancer [18] [19] [20] [21] [22] . MiR-137 could promote the recovery of spinal cord injury [23, 24] . In vivo and in vitro experiments showed that miR-137 inhibited tumor growth and promoted recovery of injury. Thus, we believe that the biological safety of miR-137 has been demonstrated. However, the role and molecular mechanism of miR-137 and PTN in hypertrophic scars remain unclear.
PTN has mitogenic effects on epithelial cells, endothelial cells, and fibroblasts [8] . Cell proliferation can be promoted by the regulated function of PTN on cell cycle-related proteins (e.g. cyclins D1 and B1). The results from this study showed that high PTN expression significantly correlates with cell metastasis. It has been reported that PTN is overexpressed in hypertrophic scars [8] , but the specific underlying mechanisms remain unclear.
In this study, miRNA expression profiling was performed and a unique miRNA signature associated with hypertrophic scar development was identified. Ten miRNAs (miR-137, miR-627-3p, miR-219b-5p, miR-96-3p, miR-548c-3p, miR-384, miR-670-3p, miR-5691, miR-3193-3p, and miR-6805-3p) were found to have a lower expression in hypertrophic scars, and 8 miRNAs (miR-5692b, miR-190a-3p, miR-513a-3p, miR-1279, miR-514b-3p, miR-19a-3p, miR-29b-3p, and miR-3974) were upregulated in hypertrophic scars. The majority of these miRNAs have been reported to function as oncogenes or tumor suppressors, which supports the assumption of similar excess proliferation in hypertrophic scars and cancer cells [25] . Our analysis showed that miR-137 was significantly downregulated in hypertrophic scar tissues. Real-time PCR also confirmed that miR-137 decreased by nearly two-thirds compared with normal tissues. Here, we demonstrated that miR-137 regulated PTN expression by directly targeting the PTN 3'-UTR. We also demonstrated that transfection of fibroblasts with an miR-137 mimic decreased the expression of PTN, while inhibition of miR-137 enhanced PTN expression. Furthermore, we found that miR-137 could inhibit fibroblast differentiation, as demonstrated by reduced expression of α-SMA, vimentin, and COL1A. Moreover, miR-137 significantly inhibited the proliferation and metastasis of fibroblasts, as shown by the results of the MTT and transwell assays. The expression levels of cyclin B1 and MMP9 could be inhibited by the miR-137 mimic. This suggests that fibroblast proliferation and metastasis were promoted by PTN activation and that this effect was mediated by decreased PTN expression resulting from overexpression of miR-137. Although further in vivo experiments are needed to verify our results, we have demonstrated that inhibition of miR-137 expression allows promotion of proliferation and metastasis of fibroblasts.
Conclusion
The results of this study suggest that miR-137 is a suppressor that exerts its effect through regulation of PTN signaling in hypertrophic scars and provides a potential target for therapy.
